Candel Therapeutics Analyst Price Targets

Candel Therapeutics Inc

CADLNASDAQ

Trade with Public

$8.68

0.465.66%

Ult. Agg.: Oct 20, 10:14 AM

$8.16

-0.05-0.61%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Candel Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Candel Therapeutics (CADL).

Price Target Range — 8 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$20Upside to Avg. PT+131.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 21, 2026	B of A Securities	Alec Stranahan	Upgrade	Neutral→Buy	$12→$18
Aug 14, 2026	B of A Securities	Alec Stranahan	PT Raise	Neutral	$9→$12
Aug 13, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$23
Jul 13, 2026	Stifel	Stephen Willey	Initiate	Buy	$22
Apr 20, 2026	Cantor Fitzgerald	—	Initiate	Overweight	—
Mar 18, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$22→$26
Mar 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$24→$22
Mar 13, 2026	Canaccord Genuity	John Newman	Maintained	Buy	$25
Dec 8, 2025	Stephens & Co.	Sudan Loganathan	Maintained	Overweight	$15
Nov 21, 2025	Freedom Broker	Ilya Zubkov	PT Raise	Buy	$13→$14
Nov 14, 2025	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$25→$24
Oct 28, 2025	Stephens & Co.	Sudan Loganathan	Initiate	Overweight	$15
Oct 21, 2025	LifeSci Capital	—	Initiate	Outperform	$16
Sep 29, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$23
Sep 3, 2025	B of A Securities	Alec Stranahan	Downgrade	Buy→Neutral	$13→$7
Jul 14, 2025	Freedom Broker	Ilya Zubkov	Initiate	Buy	$13
Jun 30, 2025	HC Wainwright & Co.	Andrew Fein	Assumes	Buy	$23
Apr 11, 2025	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$19
Mar 14, 2025	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$19
Feb 26, 2025	Canaccord Genuity	John Newman	PT Raise	Buy	$20→$25

More with Benzinga EdgeGet Access

Analyst Ratings News

This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Analysts upgraded MAC, INVH, CIEN, AMH and CADL, raising ratings and several price targets.

Avi Kapoor

PRO
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.

Benzinga Newsdesk

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

Cantor Fitzgerald initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Overweight rating.

Benzinga Newsdesk

Candel Therapeutics Inc

Candel Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

PRO
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Candel Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

PRO
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

People Also Watch

People Also Watch

Candel Therapeutics Inc

Candel Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

PROB of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PROB of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PROHC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PROStifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PROCantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Candel Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

PROB of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PROB of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PROHC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PROStifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PROCantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

People Also Watch

People Also Watch

PRO
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

PRO
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating